


Supplementary Figures 1-3

Supplementary Figure 1




Supplementary Figure 1. Identification of OT-I mice and enrichment of CD8⁺ T cells from OT-I.

Blood was drawn intravenously from OT-I mice. Following direct blood staining with α -CD8⁺-APC, and α -Vβ5.1-PE as well as α -Vα2 TCR-FITC to mark the OT-I specific transgenic α and β chain of cytotoxic T

cells, cell surface expression was determined by FACS analysis. Analysis was started with the FSC/SSC dot plot to set a marker-unspecific lymphocyte gate (left panel in **(A)** and **(B)**). Cells in this lymphocyte gate were used to identify cytotoxic T cells, known to express CD8⁺ (CD8⁺-APC) as shown in the middle panel of **(A)** and **(B)**. Finally, we utilized these CD8⁺ cells to determine whether these cells express the transgenic TCR (V β 5.1/V α 2). The result is depicted in the right panel of **(A)** and **(B)**, showing that all CD8⁺ T cells express V β 5.1/V α 2 in **(A)** and only less in **(B)**. Following single cell preparation and erythrolysis, CD8⁺ T cells were enriched **(C)** as described in “Methods” by the Dynabeads FlowComp Mouse CD8 kit. Enrichment was from around 25% (as shown in the left panel) of splenocytes to approximately 93% following purification (upper right panel). Roughly 1% of CD8⁺ T cells remain in the flow through (lower right panel). A representative isolation is shown.


Supplementary Figure 2



Supplementary Figure 2. Schematic representation of the used experimental animal approaches.

(A) Organ damage is determined following twenty-four hours h after CLP operation. **(B)** Survival of mice is analyzed for seventy-two hours following CLP-operation and, as indicated, ten days after hydrodynamic injection (HDI) of a transposon-based sleeping beauty system. **(C)** As a pharmacological setup the effect of recombinant PD-L1-Fc, directly applied following CLP operation, is determined twenty-four hours after CLP.

Supplementary Figure 3



Supplementary Figure 3. Functional expression of PD-L1 in Hepa1-6 cells. (A) and (B) Hepa1-6 cells were lentivirally transduced as described in “Methods” with a control vector (CV) and a vector encoding for PD-L1 coupled to EGFP (PD-L1 EGFP). EGFP expression was determined by (A) FACS analyses and (B) Western blotting, which was stained for EGFP (left panel) and PD-L1 (right panel) expression